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Introduction: The treatment of acute coronary syndrome (ACS) includes the administration of aspirin.
Current guidelines recommend chewing aspirin tablets to increase absorption. While this is intuitive,
there are scant data supporting this recommendation. The purpose of this study is to assess which of 3
different aspirin formulations is most rapidly absorbed after ingestion.
Methods: A prospective, open-label, 3-way crossover volunteer study at a tertiary university medical
center with human subjects 18 years or older. Fasted subjects were randomly assigned to receive
aspirin 1,950 mg as (1) solid aspirin tablets swallowed whole, (2) solid aspirin tablet chewed then
swallowed, or (3) a chewable aspirin formulation chewed and swallowed. Serum salicylate
measurements were obtained over a period of 180 minutes. Pharmacokinetic parameters were
determined.
Results: Thirteen males and 1 female completed all 3 arms of study. Peak serum salicylate
concentrations were seen at 180 minutes in all groups. Mean peaks were 10.4, 11.3, and 12.2 mg/dL in
groups 1, 2, and 3, respectively. Mean area under the time concentration was 1,153, 1,401, and 1,743
mg-min/dL in groups 1, 2, and 3, respectively. No measurable salicylate concentrations were seen in 6
subjects in group 1 at 60 minutes as compared to 1 subject in group 2. All subjects in group 3 had
measurable levels at 45 minutes. There were no adverse effects in any of the subjects during the study
period.
Conclusion: Our data demonstrate that the chewable aspirin formulation achieved the most rapid rate
of absorption. In addition, the chewable formulation absorption was more complete than the other
formulations at 180 minutes. These data suggest that in the treatment of ACS, a chewable aspirin
formulation may be preferable to solid tablet aspirin, either chewed or swallowed. [West J Emerg Med.
2011;12(4):381–385.]
INTRODUCTION
Current standard practice in the treatment of acute
coronary syndrome (ACS) by emergency medicine physicians,
internists, and cardiologists, as well as prehospital personnel,
includes the rapid administration of aspirin. This is based upon
its known antiplatelet effects to decrease clot formation and
propagation. The second International Study of Infarct Survival
demonstrated a reduction in mortality of 23% when aspirin was
administered in acute myocardial infarction.
1 These
investigators recommended that the ﬁrst dose of enteric-coated
aspirin be either crushed, chewed, or sucked to increase
absorption. In clinical practice, patients with suspected ACS
are either given chewable aspirin or an intact aspirin tablet to be
chewed or swallowed whole. Both the American Heart
Association and the American College of Cardiology
recommend that aspirin tablets be chewed to increase
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2,3 While this is intuitive, there are scant data
supporting this recommendation.
Previous studies have compared various aspirin
formulations but no 1 study has directly evaluated swallowing
solid tablets whole compared to chewing and swallowing a
solid tablet or ingesting a chewable tablet formulation.
4–6 More
recently, both topical and rectal salicylate formulations have
also been evaluated.
7,8 However, these studies involved in vivo
human volunteer subjects, not patients with ACS.
We sought to identify which aspirin formulation is most
rapidly absorbed, with a null hypothesis that there is no
difference in pharmacokinetic parameters between various
formulations of aspirin when administered by the oral route.
METHODS
This was a prospective, open-label, 3-way crossover
human volunteer study with subjects acting as their own
controls. The study was approved by the university’s human
subjects committee and was performed at a tertiary university
medical center. Inclusion criteria were as follows: healthy
volunteers 18 years of age or older, of either gender or any
ethnicity. Subjects could not have used aspirin or other
nonsteroidal anti-inﬂammatory drugs (NSAID) within 7 days
of the study. Exclusion criteria included history of aspirin or
NSAID hypersensitivity; recent ingestion of anticholinergic,
opioid, or other medications affecting gastrointestinal motility;
history of peptic ulcer disease or bleeding disorder; history of
kidney or liver problems; or pregnancy. Age, weight in
kilograms, gender, and ethnicity were recorded. A urine
pregnancy test was performed before each arm of the study to
ensure female subjects were not pregnant.
On each study day, subjects were directly observed
ingesting a total dose of 1,950 mg unbuffered aspirin
administered by a study nurse. Subjects were randomly
assigned to receive aspirin tablets: group 1 (solid) received six
325-mg aspirin tablets swallowed whole; group 2 (solid-
chewed), six 325-mg aspirin tablets chewed then swallowed;
and group 3 (chewable), twenty-four 81-mg chewable
formulation aspirin tablets that were chewed and swallowed
(Kirkland Signature Aspirin 325-mg nonenteric coated solid
tablets, Perrigo Company, Allergan, Michigan, or St Joseph’s
Chewable Aspirin tablets 81 mg, McNeil Pharmaceuticals, Fort
Washington, Pennsylvania). We used a dose of 1,950-mg
aspirin after preliminary data showed inability to obtain
measurable salicylate concentrations at a dosage of 325 mg.
Based on population pharmacokinetic data, for the dose of
1,950 mg, the maximum peak salicylate concentration would
be expected to be at the high end of the therapeutic range (5–25
mg/dL).
9
Therewas awashout period of a minimum of 7 days before
each arm of the study. Subjects were subsequently randomly
assigned before each arm. All doses were administered with a
standardized volume of 240 mL of water after fasting for a
minimum of 12 hours.
Serum salicylate measurements were obtained at baseline
and 5, 10, 15, 20, 30, 45, 60, 120, and 180 minutes after
Table. Demographic data and initial salicylate concentrations (mg/dL) in subjects*
Subject Age, y Weight, kg Sex
Tinit
†
Group 1
(Solid)
Group 2
(Solid-Chewed)
Group 3
(Chewable)
1 21 66.0 Male 45 20 15
2 22 75.1 Male 180 30 30
3 51 70.3 Male 20 30 10
4 26 74.2 Male 45 30 15
5 22 75 Male 30 30 30
6 54 78.3 Male 20 15 15
7 37 76.2 Male 15 20 15
8 21 88.1 Male 120 60 45
9 26 70.0 Male 180 180 45
10 61 85.9 Male 20 30 15
11 30 71.7 Male 120 20 20
12 25 53.8 Female 180 20 15
13 20 70.9 Male 120 30 15
14 21 70.0 Male 5 5 15
Mean 31.2 73.3 76 min 37 min 21 min
* P , 0.05 for solid versus chewable, P . 0.05 for solid versus solid-chewed and chewable versus solid-chewed.
† Tinit is the time to initial measurable salicylate concentration.
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performed at the university medical center chemistry
laboratory.
Pharmacokinetic parameters were determined by visual
inspection of graph, for example, initial salicylate
concentration (C0), time to initial salicylate concentration
(Tinit), peak salicylate concentration (Cmax), and time to peak
salicylate concentration (Tmax). The area-under-the
concentration-time curve was calculated with the trapezoidal
method from 0 to 3 hours (AUC3h). Statistical analyses
included descriptive statistics of patient demographics and a 2-
tailed t-test with correction for continual data, with a P value
less than or equal to 0.05 being considered a statistically
signiﬁcant difference. All analyses were performed with SPSS
for Windows version 16.0 (SPSS Inc, Chicago, Illinois).
Serum salicylate concentrations were determined with a
Beckman Coulter SYNCHRON LX Clinical System (Brea,
California). The system uses an immunoassay that catalyzes
conversion of salicylate and nicotinamide adenine dinucleotide
(reduced) to catechol and nicotinamide adenine dinucleotide in
the presence of oxygen. The measurable salicylate
concentrations range from 4 to 100 mg/dL.
10
RESULTS
Fourteen subjects (13 male and 1 female) were recruited
and all completed all 3 arms of the study. All subjects fasted for
a minimum of 12 hours before the study with the exception of
water ingestion ad libitum. The mean age of subjects was 31.2
years (20–61 years) with a mean weight of 73.3 kg (53–88 kg).
Nine were Caucasian; 4, Asian; and 1, Hispanic. Demographic
data and Tinit are presented in the Table. The Cmax was seen at
180 minutes in all groups. The mean Cmax was 10.4, 11.3, and
12.2 mg/dL in groups 1 (solid), 2 (solid-chewed), and 3
(chewable), respectively. There was a statistically signiﬁcant
difference in Cmax between all groups (group 1 [solid] to group
3 [chewable], P¼0.021; group 2 [solid] to group 3 [chewable],
P ¼0.001) except when comparing solid to solid-chewed
(group 1 [solid] to group 2 [solid-chewed], P¼0.28). It should
be noted that levels were still increasing at 3 hours and
therefore, the true Cmax mayhave been higher. Themean AUC3h
was 1,153, 1,401, and 1,743 mg-min/dL in groups 1 (solid), 2
(solid-chewed), and 3 (chewable), respectively. There was
statistically signiﬁcant difference in AUC3h between all groups
(group 1 [solid] to group 3 [chewable], P ¼ 0.002; group 2
[solid-chewed] to group 3 [chewable], P , 0.001) except when
solid was compared to solid-chewed (group 1 [solid] to group 2
[solid-chewed], P¼ 0.166). Of note, 6 of the 14 subjects in
group 1 (solid) had no measurable salicylate concentration at
60 minutes, as compared to 1 subject in group 2 (solid-chewed)
with no measurable concentration. Conversely, all subjects in
group 3 (chewable) had measurable concentrations at 45
minutes. Furthermore, 9 of the subjects in the chewable group
had measurable salicylate concentrations at 15 minutes as
compared to only 2 in group 1 (solid) and 2 in group 2 (solid-
chewed). No subjects reported any adverse effects during the
entire course of the study or afterwards. There were no adverse
effects in any of the subjects during any of the study periods.
DISCUSSION
Aspirin or acetylsalicylic acid is an acetylated form of
salicylic acid with a pKa of 3.5 and a volume of distribution of
0.1 to 0.3 L/kg and is approximately 90% plasma protein bound
at therapeutic levels.
11 This acetylation is a necessary
component for its antiplatelet effects. However, as aspirin is
rapidly deacetylated in vivo, salicylic acid concentrations are
measured clinically. Aspirin selectively acetylates the hydroxyl
group of a serine residue on the prostaglandin H2 synthase
enzyme.
12 This results in the loss of the cyclooxygenase
activity for the life of the platelet.
13 Aspirin has been shown in a
number of studies to be of beneﬁt in treating patients with
ACS.
1,14
The treatment of ACS is time-dependent and there are a
number of outcome measures, which are routinely evaluated
(eg, ‘‘door-to-balloon’’ time for percutaneous transluminal
coronary and ‘‘door-to-needle’’ time for thrombolysis). Several
studies have suggested improved outcomes with earlier aspirin
administrationfor patientswithacutemyocardialinfarction.
15–17
The purpose of this study was to determine which
formulation of aspirin tablets achieves the most rapid rate of
absorption. Our data demonstrate that administering a
chewable aspirin formulation achieved more rapid absorption
at the doses we administered. We also identiﬁed that solid
aspirin tablets when swallowed whole had a more variable rate
of absorption compared to the chewable formulation, which
showed not only more rapid but also more complete absorption.
Our study is the ﬁrst study to our knowledge directly
comparing unbuffered solid aspirin tablets, either chewed or
swallowed whole, to a chewable formulation of aspirin.
A 3-armed crossover study was previously performed in
human volunteers receiving either buffered aspirin 325 mg as
a solid tablet, chewed or swallowed whole, compared to an
Alka-Seltzer solution (Bayer, Morristown, New Jersey)
containing 325 mg aspirin.
4 These authors did not have a
chewable aspirin arm of the study. The maximum salicylate
concentrations were seen at 1 hour in both the chewable and
Alka-Seltzer arms compared to 2 hours when tablets were
swallowed whole. In addition, the peak salicylate
concentrations were higher in the chewable arm compared to
the other 2 arms. The maximal beneﬁcial antithrombotic
effect of aspirin is seen when platelet inhibition exceeds 90%
of baseline.
4 Ninety percent platelet inhibition was seen at
between 13 to 14 minutes after chewing an aspirin tablet as
compared to 19 to 20 minutes and 25 to 26 minutes after
Alka-Seltzer and whole tablet ingestion, respectively.
One general limitation in extrapolating from the above
study is the use of buffered tablets and Alka-Seltzer, as many
institutions and prehospital providers use unbuffered aspirin
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carbonate) are added to minimize gastric upset by creating
increased local pH, thereby limiting absorption in the stomach.
Alka-Seltzer contains sodium bicarbonate for similar reasons.
By causing a higher intraluminal pH, and subsequent increase
in fraction of ionized salicylate, these buffering agents may
delay absorption. Unbuffered aspirin results in a lower gastric
pH and increased absorption from the stomach than does
buffered aspirin.
18 We suggest only unbuffered aspirin be used
in patients with ACS to facilitate more rapid and complete
absorption.
In another crossover volunteer study, subjects were given a
325-mg aspirin tablet swallowed whole, four 81-mg chewable
aspirin tablets, or an Alka-Seltzer solution containing 325-mg
aspirin.
5 Peak salicylate concentrations were seen at 40
minutes, the endpoint of their study, in all groups. However,
both the chewable and the Alka-Seltzer solution had higher
peak concentrations than aspirin tablet swallowed whole.
Interestingly, the time to greater than 90% platelet inhibition
was seen within 10 minutes in the chewable arm compared to
15 minutes and 25 minutes in the Alka-Seltzer and solid tablet
arms, respectively. These data appear to support using a
chewable aspirin formulation.
In another triple crossover study, volunteers were
administered one 81-mg, two 81-mg, or four 81-mg chewable
aspirin tablets and the time and degree of platelet inhibition was
measured.
6 For all subjects in all 3 arms, greater than 90%
platelet inhibition was seen at 30 minutes. However, in the
initial phase of their study, 3 subjects receiving 81 mg and 1
subject given 162 mg did not have platelet inhibition at 15
minutes, whereas all subjects receiving 324 mg achieved
platelet inhibition at 15 minutes. These results suggest it may
be preferable to give a higher dose of aspirin, particularly to
patients with ACS.
We theorize that a more rapid absorption was observed in
group 3 (chewable) after ingesting the chewable formulation
aspirin, for several reasons. First, in order for a drug to be
absorbed it must ﬁrst be solubilized. Chewable formulations
are softer tablets that dissolve more quickly than hard-pressed
tablets meant for swallowing intact. Furthermore, giving
twenty-four 81-mg chewable tablets compared to six 325-mg
solid tablets would result in an increase in total amount of both
gastric and small intestinal surface area coverage. A larger
amount of surface area in contact with aspirin would be
expected to increase the amount of aspirin absorbed. Giving
multiple chewable tablets, that is, four 81-mg tablets compared
to just one 325-mg solid aspirin tablet, should mimic this
surface area effect. This should increase rapidity and
completeness of platelet inhibition, the desired endpoint in the
treatment of ACS.
Higher-dose administration has been associated with an
increased incidence of bleeding in persons chronically
ingesting aspirin.
19 A more recent study using combined
GUSTO I and III data in patients with ST-elevation myocardial
infarction suggests a possible increase in bleeding
complications with 325-mg aspirin compared to 162 mg.
20
There is also a concern of increased gastrointestinal upset
at higher dosages. Of note, none of our subjects had any
adverse events, including gastrointestinal upset, after ingesting
1,950 mg on 3 separate occasions during or after the study
period.
In patients with suspected ACS, the use of two 81-mg (162
mg) and possibly four 81-mg (324 mg) chewable tablets may be
preferable to increase intraluminal surface area to aspirin and
subsequent absorption and platelet inhibition.
LIMITATIONS
The major limitation of our study is that we did not
measure platelet inhibition activity but rather serum salicylate
concentrations, as this was a pharmacokinetic study. However,
aspirin is well known to inhibit platelet aggregation. Previous
data have identiﬁed that a serum salicylate concentration of
approximately 1 mg/dL is necessary to achieve platelet
inhibition greater than 90% of baseline.
4 Similar to other
studies, the lowest level of detection for the assay we used to
determine serum salicylate concentrations was 4 mg/dL.
8
Therefore, all subjects would have been expected to have ‘‘full’’
antiplatelet effects by the time we achieved measurable
concentrations. However, the delay in Tinit, particularly in group
1 (solid) after swallowing an aspirin tablet whole, suggests this
effect would be achieved later in group 1 (solid) compared to
group 2 (solid-chewed) and group 3 (chewable).
As stated previously, we used supratherapeutic doses of
1,950-mg aspirin, on the basis of preliminary data we obtained
after the administration of 325-mg tablets to 3 subjects, without
the ability to obtain measurable salicylate concentrations owing
to the sensitivity of our assay. In addition, although salicylate
does exhibit zero-order pharmacokinetics at extremely high
dosages (ie, large poisonings), at the doses we used, salicylate
follows ﬁrst-order kinetics.
21,22 One further limitation of study
is that our subject population lacked some ethnic and gender
diversity. However, it is unclear how this affects our results.
Finally, as this was a pharmacokinetic study, we used
fasting subjects. It is possible in real-world patients with ‘‘full
stomachs’’ that absorption could be further delayed owing to
decreased gastric emptying time.
CONCLUSION
Our data demonstrate that the chewable formulation of
aspirin, aswell as the chewing of solid tablets, increases the rate
of absorption. These pharmacokinetic data suggest that a
chewable formulation may be preferable to solid tablets chewed
or swallowed in treatment of ACS. However, larger prospective
studies in patients being treated for ACS are needed to see if
this is clinically signiﬁcant, ideally also assessing the degree of
platelet inhibition.
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